Cargando…

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies

The renin-angiotensin-aldosterone system (RAAS), is an old system with new fundamental roles in cancer biology which influences cell growth, migration, death, and metastasis. RAAS signaling enhances cell proliferation in malignancy directly and indirectly by affecting tumor cells and modulating angi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassani, Bahareh, Attar, Zeinab, Firouzabadi, Negar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604988/
https://www.ncbi.nlm.nih.gov/pubmed/37891636
http://dx.doi.org/10.1186/s12935-023-03080-9
_version_ 1785126966339305472
author Hassani, Bahareh
Attar, Zeinab
Firouzabadi, Negar
author_facet Hassani, Bahareh
Attar, Zeinab
Firouzabadi, Negar
author_sort Hassani, Bahareh
collection PubMed
description The renin-angiotensin-aldosterone system (RAAS), is an old system with new fundamental roles in cancer biology which influences cell growth, migration, death, and metastasis. RAAS signaling enhances cell proliferation in malignancy directly and indirectly by affecting tumor cells and modulating angiogenesis. Cancer development may be influenced by the balance between the ACE/Ang II/AT1R and the ACE2/Ang 1–7/Mas receptor pathways. The interactions between Ang II/AT1R and Ang I/AT2R as well as Ang1-7/Mas and alamandine/MrgD receptors in the RAAS pathway can significantly impact the development of cancer. Ang I/AT2R, Ang1-7/Mas, and alamandine/MrgD interactions can have anticancer effects while Ang II/AT1R interactions can be involved in the development of cancer. Evidence suggests that inhibitors of the RAAS, which are conventionally used to treat cardiovascular diseases, may be beneficial in cancer therapies. Herein, we aim to provide a thorough description of the elements of RAAS and their molecular play in cancer. Alongside this, the role of RAAS components in sex-dependent cancers as well as GI cancers will be discussed with the hope of enlightening new venues for adjuvant cancer treatment. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10604988
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106049882023-10-28 The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies Hassani, Bahareh Attar, Zeinab Firouzabadi, Negar Cancer Cell Int Review The renin-angiotensin-aldosterone system (RAAS), is an old system with new fundamental roles in cancer biology which influences cell growth, migration, death, and metastasis. RAAS signaling enhances cell proliferation in malignancy directly and indirectly by affecting tumor cells and modulating angiogenesis. Cancer development may be influenced by the balance between the ACE/Ang II/AT1R and the ACE2/Ang 1–7/Mas receptor pathways. The interactions between Ang II/AT1R and Ang I/AT2R as well as Ang1-7/Mas and alamandine/MrgD receptors in the RAAS pathway can significantly impact the development of cancer. Ang I/AT2R, Ang1-7/Mas, and alamandine/MrgD interactions can have anticancer effects while Ang II/AT1R interactions can be involved in the development of cancer. Evidence suggests that inhibitors of the RAAS, which are conventionally used to treat cardiovascular diseases, may be beneficial in cancer therapies. Herein, we aim to provide a thorough description of the elements of RAAS and their molecular play in cancer. Alongside this, the role of RAAS components in sex-dependent cancers as well as GI cancers will be discussed with the hope of enlightening new venues for adjuvant cancer treatment. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2023-10-27 /pmc/articles/PMC10604988/ /pubmed/37891636 http://dx.doi.org/10.1186/s12935-023-03080-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Hassani, Bahareh
Attar, Zeinab
Firouzabadi, Negar
The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
title The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
title_full The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
title_fullStr The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
title_full_unstemmed The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
title_short The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
title_sort renin-angiotensin-aldosterone system (raas) signaling pathways and cancer: foes versus allies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604988/
https://www.ncbi.nlm.nih.gov/pubmed/37891636
http://dx.doi.org/10.1186/s12935-023-03080-9
work_keys_str_mv AT hassanibahareh thereninangiotensinaldosteronesystemraassignalingpathwaysandcancerfoesversusallies
AT attarzeinab thereninangiotensinaldosteronesystemraassignalingpathwaysandcancerfoesversusallies
AT firouzabadinegar thereninangiotensinaldosteronesystemraassignalingpathwaysandcancerfoesversusallies
AT hassanibahareh reninangiotensinaldosteronesystemraassignalingpathwaysandcancerfoesversusallies
AT attarzeinab reninangiotensinaldosteronesystemraassignalingpathwaysandcancerfoesversusallies
AT firouzabadinegar reninangiotensinaldosteronesystemraassignalingpathwaysandcancerfoesversusallies